NR4A1 and breast cancer: Since the most common subset of BC is hormone-receptor-positive [5], many patients receive adjuvant treatments with tamoxifen or aromatase inhibitors (AI) [6] with or without gonadotropin-releasing hormone (GnRH) agonists (depending on premenopausal or post-menopausal tumor onset) [7].